Advisor
Eli Lilly and company
Indianapolis, Indiana
Niloufar Salehi completed her B.Sc. degree in Chemical Engineering in 2013 at the Sharif University of Technology in Tehran, Iran (2009–2013). Subsequently, she embarked on a research project at the University of Michigan, focused on studying the aggregation and self-assembly of asphaltene molecules using molecular dynamics (MD) simulation tools. Motivated by her passion for interdisciplinary research, Niloufar pursued Ph.D. degrees in both Chemical Engineering and Pharmaceutical Sciences at the University of Michigan from 2016 to 2021. Throughout her doctoral studies, she worked under the guidance of Professor Gregory Amidon, Professor Robert Ziff, and Professor Gordon Amidon. Her dissertation was titled “Developing models to improve oral drug product delivery in the gastrointestinal (GI) tract”. Continuing her academic journey, Niloufar held a postdoctoral research position in Professor Steven Schwendeman’s Lab at the University of Michigan from 2021 to 2022 focusing on controlled release drug delivery and further expanding her expertise in these areas. Niloufar joined the Biopharmaceutics Modeling Group led by Dr. David Sperry in the Synthetic Molecule Design and Development organization at Eli Lilly & Company in 2023. Niloufar will be contributing to in silico and in vitro based predictions of oral formulation absorption in her new role.
Disclosure information not submitted.
Symposium: An Accelerated Development of Poorly Soluble Drugs Using Predictive Tools
Tuesday, October 22, 2024
9:00 AM – 11:00 AM MT